Researchers of a study assessed the clinicopathological features and survival in Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS). The findings were published in Haematologica.
In this retrospective study, the researchers assessed 70 cases of EBV-positive DLBCL-NOS among a larger population of 1,696 DLBCL-NOS cases diagnosed between 2006 and 2019. At diagnosis, the median patient age was 68.5 years; with 79% of the cases presenting with an advanced-stage disease (III-IV).
According to the results, a total of 46 cases presented a polymorphic pattern, and 21 were monomorphic. All 46 cases had a non-germinal center B phenotype, with the majority of tumor cells expressing CD30 and programmed death ligand 1 (98% and 95%, respectively). The researchers observed type II and III EBV latency in 88% and 12% of the cases, respectively. The study found that patients were treated with immunochemotherapy (59%) or chemotherapy (22%), and 19% received palliative care due to advanced age and poor performance status.
Overall, older age (>50 years) and hemophagocytic lymphohistiocytosis were associated with shorter PFS and OS in multivariate analysis (PFS: hazard ratio [HR]=14.01; 95% confidence interval [CI], 2.34-83.97; and HR=5.78; 95% CI, 2.35-14.23; OS: HR=12.41; 95% CI, 1.65-93.53; and HR=6.09; 95% CI, 2.42-15.30, respectively).
“[Using] a control cohort of 425 EBV- DLBCL-NOS, EBV positivity was associated with a shorter OS outcome within patients >50 years, but not in younger patients,” the researchers wrote of the results.